Medigene has created an automated method for detecting newly created cancer molecules called neoantigens as they arise in a developing tumor.

The company believes the high-volume method will prove more efficient at spotting the molecules and evaluating their suitability as treatment targets. This means the method could help improve cancer immunotherapy, facilitating the development of more personalized and safer treatments.

Medigene’s CEO, Dr. Dolores Schendel, will discuss the method on the final day of the Immuno-Oncology Summit in Boston on Sept. 1, according to a company press release. The conference started Aug. 28.

The presentation will deal with how Medigene’s technology for developing new types of T-cell-based treatments and dendritic cell vaccines could also lead to therapies that target neoantigens.


Source: Immuno-Oncology News